Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility

PloS One
Jeffrey W CraigOlga Pozdnyakova

Abstract

"Double-hit" and "double-expressor" lymphomas represent distinct but overlapping subsets of aggressive B-cell non-Hodgkin lymphoma. The high rates of bone marrow involvement by these lymphomas pose a major therapeutic challenge due to the chemotherapy-resistant nature of the bone marrow microenvironment and the limited utility of rituximab-based salvage regimens in patients with relapsed/refractory disease. Preclinical studies utilizing high-dose cyclophosphamide in combination with the anti-CD52 monoclonal antibody alemtuzumab have recently shown promise in the treatment of intramedullary disease, and a Phase I human trial is now underway. In support of such efforts, here we perform CD52 target validation on a series of double-hit (n = 40) and double-expressor (n = 58) lymphomas using immunohistochemistry. CD52 expression levels varied considerably across samples, however positive staining was observed in 75% of both double-hit and double-expressor lymphomas. Similarly, high levels of CD52 expression were seen in patients whose disease was associated with high-risk clinical features, including primary refractory status (73%), higher IPI score (76%), and bone marrow involvement (74%). CD52 expression was not significantly corre...Continue Reading

References

Aug 8, 2001·American Journal of Clinical Pathology·H C BertramM A Milano
Jun 27, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Tomoko WatanabeIsao Serizawa
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott J RodigJeffery L Kutok
May 16, 2008·American Journal of Clinical Pathology·Wenqing CaoLoann C Peterson
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marita ZiepertMarkus Loeffler
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tina Marie GreenMichael Boe Møller
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathalie A JohnsonRandy D Gascoyne
Jul 19, 2013·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Byung Woog KangSang Kyun Sohn
Feb 4, 2014·Cell·Christian P PallaschMichael T Hemann
Jun 20, 2014·British Journal of Haematology·Yasuhiro OkiJason R Westin
Feb 11, 2015·MAbs·Kipp Weiskopf, Irving L Weissman
Mar 11, 2015·The Journal of Experimental Medicine·Alberto Mantovani, Paola Allavena
Aug 11, 2015·Current Opinion in Oncology·Clémentine Sarkozy, Bertrand Coiffier
Sep 1, 2015·Critical Reviews in Oncology/hematology·Esmeralda Chi-Yuan TeoColin Phipps
Nov 2, 2015·Haematologica·Daniela S Krause, David T Scadden
Nov 8, 2015·The Lancet Oncology·Clémentine SarkozyBertrand Coiffier
Dec 4, 2016·Hematology·Bertrand Coiffier, Clémentine Sarkozy
Oct 7, 2017·Advances in Therapy·Gilles SallesDavid G Maloney

❮ Previous
Next ❯

Citations

May 2, 2019·Cancer Discovery·Chen LossosDavid M Weinstock

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
biopsies
biopsy
flow cytometry

Software Mentioned

R

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Sonali M Smith
La Revue du praticien
Corinne Haioun, Félix Reyes
Hematology/oncology Clinics of North America
Thomas S LinJohn C Byrd
© 2022 Meta ULC. All rights reserved